Precision Medicine in AD: Castle’s Pipeline AD GEP Test May Help Patients Avoid Trial-and-Error Treatment Cycles December 23, 2024
AD Pipeline Watch: Corvus Pharmaceuticals’ ITK Inhibitor Shows Promise in Phase 1 AD Trial December 18, 2024
Arcutis Submits Roflumilast Cream 0.05% (Zoryve) sNDA to the FDA for Mild to Moderate AD in Children Aged 2 to 5 December 16, 2024
